CTOs on the Move

Asklepios BioPharmaceutical

www.askbio.com

 
Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.askbio.com
  • 20 T.W. Alexander Drive Suite 110
    Research Triangle Park, NC USA 27709
  • Phone: 919.561.6210

Executives

Name Title Contact Details

Funding

Asklepios BioPharmaceutical raised $235M on 04/11/2019

Similar Companies

Dewpoint Therapeutics

Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.

Michigan Medicine

Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.

Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme`s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company`s partners make progress developing and commercializing their products being developed using ENHANZE®

Schleicher and Schuell BioScience

Schleicher and Schuell BioScience is a Keene, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Labquip

Labquip Ltd is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.